MBX Biosciences, Inc. Common Stock
NASDAQ: MBX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter Kent Hawryluk
- Employees
- 43
- Headquarters
- Carmel, United States
- IPO year
- 2000
- Market cap
- $1.6B
- Website
- https://mbxbio.com
Loading MBX…
Loading profile data…Frequently asked questions about MBX
What does MBX Biosciences, Inc. Common Stock (MBX) do?
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a...
Where does MBX trade?
MBX Biosciences, Inc. Common Stock (MBX) trades on the NASDAQ Global Select.
What sector is MBX in?
MBX Biosciences, Inc. Common Stock (MBX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MBX Biosciences, Inc. Common Stock?
Peter Kent Hawryluk is the chief executive officer of MBX Biosciences, Inc. Common Stock (MBX).
Where is MBX Biosciences, Inc. Common Stock headquartered?
MBX Biosciences, Inc. Common Stock is headquartered in United States.
Does MBX pay a dividend?
MBX Biosciences, Inc. Common Stock (MBX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MBX go public?
MBX Biosciences, Inc. Common Stock (MBX) completed its initial public offering in 2000.